Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives Consensus Rating of “Moderate Buy” from Brokerages

Lucid Diagnostics Inc. (NASDAQ:LUCD) has received an average recommendation of “Moderate Buy” from the five research firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $3.9375.

Several equities research analysts have issued reports on LUCD shares. Ascendiant Capital Markets lifted their target price on shares of Lucid Diagnostics from $8.00 to $8.25 and gave the company a “buy” rating in a research report on Wednesday, December 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lucid Diagnostics in a report on Monday, December 29th. Finally, Wall Street Zen cut shares of Lucid Diagnostics from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th.

Lucid Diagnostics Stock Performance

Shares of NASDAQ LUCD opened at $1.25 on Tuesday. The business has a 50-day moving average of $1.30 and a 200-day moving average of $1.18. The firm has a market capitalization of $172.10 million, a price-to-earnings ratio of -1.20 and a beta of 1.18. Lucid Diagnostics has a 12 month low of $0.95 and a 12 month high of $1.80.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Centiva Capital LP bought a new stake in Lucid Diagnostics during the third quarter worth about $25,000. Sprott Inc. bought a new position in shares of Lucid Diagnostics during the 3rd quarter valued at about $25,000. SG Americas Securities LLC purchased a new position in shares of Lucid Diagnostics during the 3rd quarter valued at about $26,000. Quadrature Capital Ltd purchased a new position in shares of Lucid Diagnostics during the 2nd quarter valued at about $29,000. Finally, Abel Hall LLC bought a new stake in Lucid Diagnostics in the 4th quarter worth approximately $33,000. Institutional investors own 74.01% of the company’s stock.

About Lucid Diagnostics

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.